07 July 2020 : Laboratory Research
Induction and Regulation of the Immunoproteasome Subunit β5i (PSMB8) in Laryngeal and Hypopharyngeal Carcinoma Cells
Nan-Xiang Chen1BCEF, Kun Liu1BC, Xuan Liu2A, Xin-Xin Zhang1AD, Dong-yi Han1ADF*DOI: 10.12659/MSM.923621
Med Sci Monit 2020; 26:e923621
Table 1 Classification and application of PIs.
| Type | Drug name | Binding type | Target affinity | Status |
|---|---|---|---|---|
| Boronates | Bortezomib (PS-341) | Reversible | β5>β1 | Approved by the FDA for the treatment of multiple myeloma and lymphoma |
| Ixazomib (MLN-9708/2238) | Reversible | β5>β1 | Approved by the FDA for the treatment of multiple myeloma in combination with other drugs | |
| Delanzomib (CEP-18770) | Reversible | β5>β1 | Phase I and Phase II studies | |
| Salinosporamides | Marizomib (NPI-0052) | Nonreversible | β5>β2>β1 | Approved by the FDA for the treatment of malignant glioma |
| Epoxyketones | Carfilzomib (PR171) | Reversible | β5 | Approved by the FDA for the treatment of multiple myeloma |
| Oprozomib (ONX-0912, PR-047) | Nonreversible | β5 | Phase I and Phase II studies |